麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PRELIMINARY ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR 2020

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined by the provisions of Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571) of the Laws of Hong Kong by Livzon Pharmaceutical Group Inc.* 麗珠醫藥集團股份有限公司 (the "Company", together with its subsidiaries, the "Group").

The Company and all members of the board of directors guarantee that the information stated in this announcement is true, accurate and complete and does not contain any false representation, misleading statement or material omission.

Important: the financial data for the year 2020 set out in this announcement represents figures of preliminary estimations only and has not been audited by an auditing firm. As a result, differences may be found between the data below and the definitive financial data disclosed in the 2020 Annual Report. Investors are advised to be cautious about investment risks involved.

I. PRELIMINARY RESULTS FOR THE PERIOD

1. Period for the preliminary estimated results： 1 January 2020 to 31 December 2020
2. Preliminary estimated operating results： increase over the corresponding period last year

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the listed company	Profit: approximately RMB1,628.5943 million – RMB1,824.0256 million	Profit: RMB1,302.8754 million
	Increased by approximately 25% – 40% as compared to the corresponding period last year	
Net profit attributable to the shareholders of the listed company after deducting the extraordinary gain or loss	Profit: approximately RMB1,370.2654 million – RMB1,489.4190 million	Profit: RMB1,191.5352 million
	Increased by approximately 15% – 25% as compared to the corresponding period last year	
Basic earnings per share (RMB/share)	Profit: approximately RMB1.72 – RMB1.93 per share	Profit: RMB1.39 per share

II. COMMUNICATION WITH THE ACCOUNTING FIRM

Regarding to the preliminary estimated results, the Company has communicated with the accounting firm for annual audit and there is no disagreement among us. The preliminary estimated results have not been audited by the accounting firm.

III. EXPLANATION FOR THE CHANGES IN RESULTS

The annual results of the Company for the year 2020 have increased as compared to the corresponding period last year, which was mainly attributable to:

1. In 2020, the sales of some prescription medicine products of the Company did not reach the expected level as a result of the pandemic. Nevertheless, there was a rapid substantial increase in the sale of Ilaprazole Sodium for Injection (注射用艾普拉唑鈉), a major product of chemical drug preparation, as compared with that of the previous year together with a continuous greater growth in the sales of Leuprorelin Acetate Microspheres for Injection (注射用醋酸亮丙瑞林微球), Perospirone Hydrochloride Tablets (鹽酸哌羅匹隆片) and Fluvoxamine Maleate Tablets (馬來酸氟伏沙明片) compared with those of the previous year, and with the benefit from the pandemic, a significant growth in the sale of Anti-viral Granules (抗病毒顆粒), a major product of Traditional Chinese drug preparation, as compared with that of the previous year, and additional sales of diagnostic kits for antibodies to novel coronavirus, which contributed to a significant support to the stable growth of the overall performance of the Company.

2. The government subsidies increased year-on-year and the disposal of equity of Jiangsu Ni Ke Medical Device Co., Ltd.* (江蘇尼科醫療器械有限公司) has realized an increase in investment gains.

IV. RISK WARNING AND OTHER RELEVANT INFORMATION

1. Figures related to these preliminary estimated results are arrived based on the estimated calculation of the Company, and have not been audited by the accounting firm;

2. Detailed financial information will be disclosed in the 2020 Annual Report of the Company. Potential investors are advised to pay attention to the risks associated with the investment.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc.*
Yang Liang
Company Secretary

Zhuhai, China
25 January 2021

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

** For identification purpose only*